Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation

Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.

Tech Transfer regular column feature image

Below is Scrip’s regular roundup, including information from Strategic Transactions, of recent technology transfer agreements and collaborations between companies and academic or other research institutions.

Privately held Be Cool Pharmaceutics LLC has in-licensed a drug composition patent from the University of Alaska Fairbanks that covers the study of inducing a hibernation-like state in a number of diseases, starting with cardiac arrest occurring outside the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business